In Q4, 2017, ISR asked 730 buyers of outsourced manufacturing services about upcoming changes to their pipeline and how it might impact their outsourcing practices. Respondents were asked to indicate their level of agreement with each of the following statements; the majority (55%) agree – strongly agree their organization will increase focus on biomanufacturing, including biosimilars. CAR T-cell therapies followed with 48% of respondents mentioning an increased focus on this type of cancer therapy. View File